Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).

Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV.

J Clin Pharmacol. 2019 Dec 4. doi: 10.1002/jcph.1559. [Epub ahead of print]

PMID:
31802506
2.

Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.

Karam R, Conner B, LaDuca H, McGoldrick K, Krempely K, Richardson ME, Zimmermann H, Gutierrez S, Reineke P, Hoang L, Allen K, Yussuf A, Farber-Katz S, Rana HQ, Culver S, Lee J, Nashed S, Toppmeyer D, Collins D, Haynes G, Pesaran T, Dolinsky JS, Tippin Davis B, Elliott A, Chao E.

JAMA Netw Open. 2019 Oct 2;2(10):e1913900. doi: 10.1001/jamanetworkopen.2019.13900.

3.

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients.

Sayan M, Abou Yehia Z, Gupta A, Toppmeyer D, Ohri N, Haffty BG.

Front Oncol. 2019 Oct 1;9:970. doi: 10.3389/fonc.2019.00970. eCollection 2019.

4.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr.

JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print]

PMID:
31566680
5.

5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost.

Gupta A, Khan AJ, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N, Goyal S, Moore DF, Eladoumikdachi F, Toppmeyer D, Haffty BG.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):267-274. doi: 10.1016/j.ijrobp.2019.05.063. Epub 2019 Jun 5.

PMID:
31175905
6.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
7.

Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy.

Manne S, Smith B, Mitarotondo A, Frederick S, Toppmeyer D, Kirstein L.

Patient Educ Couns. 2019 May;102(5):902-908. doi: 10.1016/j.pec.2018.12.008. Epub 2018 Dec 10.

PMID:
30553577
8.

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517.

PMID:
30475950
9.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P.

Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.

PMID:
30475947
10.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.

11.

Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.

Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19.

12.

Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay.

Farber-Katz S, Hsuan V, Wu S, Landrith T, Vuong H, Xu D, Li B, Hoo J, Lam S, Nashed S, Toppmeyer D, Gray P, Haynes G, Lu HM, Elliott A, Tippin Davis B, Karam R.

Front Oncol. 2018 Jul 27;8:286. doi: 10.3389/fonc.2018.00286. eCollection 2018.

13.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

14.

Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer-specific Mortality.

Arlow RL, Paddock LE, Niu X, Kirstein L, Haffty BG, Goyal S, Kearney T, Toppmeyer D, Stroup AM, Khan AJ.

Am J Clin Oncol. 2018 Dec;41(12):1246-1251. doi: 10.1097/COC.0000000000000456.

PMID:
29782362
15.

The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence.

Chan N, Toppmeyer DL.

J Clin Oncol. 2018 Apr 10;36(11):1058-1059. doi: 10.1200/JCO.2017.77.4877. Epub 2018 Feb 27. No abstract available.

PMID:
29485930
16.

Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma.

Bjørklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnæs GIG, Toppmeyer D, Riis M, Naume B, Børresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G.

Sci Rep. 2017 Jul 17;7(1):5568. doi: 10.1038/s41598-017-05537-0.

17.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

18.

Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.

Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG.

J Clin Oncol. 2017 Jun 20;35(18):2037-2043. doi: 10.1200/JCO.2016.70.7158. Epub 2017 May 1.

19.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

20.

Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?

Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D.

Semin Oncol. 2015 Aug;42(4):e67-79. doi: 10.1053/j.seminoncol.2015.07.001. Epub 2015 Jul 6. Review. No abstract available.

PMID:
26320071
21.

ACR Appropriateness Criteria® Ductal Carcinoma in Situ.

Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park CC, Suh WW, Toppmeyer D, Zook J, Haffty BG.

Oncology (Williston Park). 2015 Jun;29(6):446-58, 460-1. Review.

22.

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP.

J Clin Oncol. 2015 Jul 20;33(21):2361-9. doi: 10.1200/JCO.2014.59.5298. Epub 2015 Jun 8.

23.

Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S.

Front Oncol. 2014 Oct 9;4:277. doi: 10.3389/fonc.2014.00277. eCollection 2014. Review.

24.

Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer.

Chojecki A, Wong S, Toppmeyer D.

Am Soc Clin Oncol Educ Book. 2014:e12-5. doi: 10.14694/EdBook_AM.2014.34.e12. Review.

25.

ACR Appropriateness Criteria local-regional recurrence (LRR) and salvage surgery-breast cancer.

Halyard MY, Harris EE, Bailey L, Bellon JR, Freedman GM, Goyal S, Horst KC, Moran MS, Park CC, Suh WW, Toppmeyer D, Haffty BG.

Oncology (Williston Park). 2014 Feb;28(2):157-64, C3.

26.

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.

Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, Toppmeyer DL, Medina DJ, Ganesan S, Vazquez A, Hirshfield KM.

PLoS One. 2013 Jul 26;8(7):e69851. doi: 10.1371/journal.pone.0069851. Print 2013.

27.

Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers.

Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S.

PLoS One. 2012;7(6):e38575. doi: 10.1371/journal.pone.0038575. Epub 2012 Jun 13.

28.

Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.

Bilal E, Alexe G, Yao M, Cong L, Kulkarni A, Ginjala V, Toppmeyer D, Ganesan S, Bhanot G.

Genes Cancer. 2010 Oct;1(10):1063-73. doi: 10.1177/1947601910395583.

29.

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence.

Vazquez A, Kulkarni D, Grochola LF, Bond GL, Barnard N, Toppmeyer D, Levine AJ, Hirshfield KM.

Int J Cancer. 2011 May 15;128(10):2335-43. doi: 10.1002/ijc.25582.

30.

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes.

Mehta MS, Vazquez A, Kulkarni DA, Kerrigan JE, Atwal G, Metsugi S, Toppmeyer DL, Levine AJ, Hirshfield KM.

Breast Cancer Res Treat. 2011 Feb;125(3):861-8. doi: 10.1007/s10549-010-1062-1. Epub 2010 Jul 25.

31.

Triple-negative breast cancers and the human mammary epithelial cell hierarchy.

Ganesan S, Karantza V, Oza J, Toppmeyer D.

Breast Dis. 2010;32(1-2):49-61. doi: 10.3233/BD-2010-0322. Review.

PMID:
22045329
32.

Ixabepilone, a new treatment option for metastatic breast cancer.

Toppmeyer DL, Goodin S.

Am J Clin Oncol. 2010 Oct;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52. Review.

PMID:
20023567
33.

A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer.

Kulkarni DA, Vazquez A, Haffty BG, Bandera EV, Hu W, Sun YY, Toppmeyer DL, Levine AJ, Hirshfield KM.

Carcinogenesis. 2009 Nov;30(11):1910-5. doi: 10.1093/carcin/bgp224. Epub 2009 Sep 16.

34.

Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.

Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS.

Ann Oncol. 2009 Oct;20(10):1653-9. doi: 10.1093/annonc/mdp051. Epub 2009 Jun 2.

PMID:
19491284
35.

Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?

Tan AR, Toppmeyer DL.

Clin Cancer Res. 2008 Nov 1;14(21):6725-9. doi: 10.1158/1078-0432.CCR-07-4704. Review. No abstract available.

36.

Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer.

Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1056-63. doi: 10.1016/j.ijrobp.2008.02.066.

PMID:
18676094
37.

Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D.

J Clin Oncol. 2006 Dec 20;24(36):5652-7. Epub 2006 Nov 20.

PMID:
17116942
38.

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ.

Cancer Res. 2006 May 15;66(10):5104-10.

39.

The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.

Kelly K, Leventhal H, Andrykowski M, Toppmeyer D, Much J, Dermody J, Marvin M, Baran J, Schwalb M.

J Genet Couns. 2004 Jun;13(3):237-57.

PMID:
15604634
40.

Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutations.

Kelly K, Leventhal H, Andrykowski M, Toppmeyer D, Much J, Dermody J, Marvin M, Baran J, Schwalb M.

Psychooncology. 2005 Jan;14(1):34-48.

PMID:
15386791
41.

Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.

Kelly K, Leventhal H, Marvin M, Toppmeyer D, Much J, Dermody J, Baran J, Schwalb M.

Genet Test. 2004 Summer;8(2):139-47.

PMID:
15345111
42.

Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.

Kelly K, Leventhal H, Marvin M, Toppmeyer D, Baran J, Schwalb M.

Cancer Control. 2004 Jul-Aug;11(4):236-44.

PMID:
15284715
43.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ.

J Natl Cancer Inst. 2004 May 19;96(10):759-69.

PMID:
15150304
44.

A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.

Toppmeyer DL, Gounder M, Much J, Musanti R, Vyas V, Medina M, Orlando T, Pennick M, Lin Y, Shih W, Goodin S, Rubin E.

Med Sci Monit. 2003 Aug;9(8):PI99-104.

PMID:
12942041
45.

Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent.

Kelly K, Leventhal H, Toppmeyer D, Much J, Dermody J, Marvin M, Baran J, Schwalb M.

J Genet Couns. 2003 Aug;12(4):351-71. doi: 10.1023/A:1023905106360.

PMID:
26141175
46.

Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH.

Clin Cancer Res. 2003 May;9(5):1673-9.

48.

Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.

DiPaola RS, Rubin E, Toppmeyer D, Eid J, Butzbach D, Dvorzhinski D, Capanna T, Cairdella M, Shih JW, Goodin S, Todd MB.

Med Sci Monit. 2003 Feb;9(2):PI5-11.

PMID:
12601301
49.

A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.

Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA.

Clin Cancer Res. 2002 Dec;8(12):3710-7.

50.

A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN.

Clin Cancer Res. 2002 May;8(5):1057-64.

Supplemental Content

Loading ...
Support Center